2022年8月26日 · EBMT分析了1997年至2006年在既往ASCT后接受allo-HSCT的101例DLBCL患者，证实了allo-HSCT在具有挑战性的预治疗患者队列中的重要作用，3年非复发死亡率(NRM)为28.2%，3年 PFS为41.7%，3年OS为53.8%。

2 天之前 · Persons diagnosed with diffuse large B cell lymphoma (DLBCL) often face grim outcomes upon reaching the third line of treatment, with a reported overall survival (OS) of less than 7 months 1,2 ...

Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R-CHOP remains the mainstay of therapy ...

2022年11月15日 · Prevalence for DLBCL ranged from 20.0% to 63.9% among NHL, with about 4.2% to 24.8% of DLBCL patients R/R to frontline treatments. The 5-year overall survival (OS) rate for DLBCL patients ranged from 53.1% to 61.6%. Among R/R patients, 2-year OS rates ranged from 13.9% 16.0%.

弥漫大 B细胞淋巴瘤（Diffuse large B cell lymphoma，DLBCL）是最常见的恶性淋巴瘤亚型，国内数据显示中位诊断年龄约57岁，近30%的患者诊断时年龄超过70岁，且发病率随年龄的增加而上升。根据中国社会保障协会公布的《中国老龄化研究报告2022》，2020年我国65岁以上 ...

2023年9月6日 · 新诊断弥漫性大b细胞淋巴瘤(dlbcl)的标准方案为r-chop。虽然50%-60%的患者可通过该方案治愈，但有10%-15%的患者出现原发难治性疾病，30%-40%的患者在诊断后的前2年内复发。直到最近，复发/难治性dlbcl (r/r)的唯一治愈性选择仍是挽救性化疗和造血细胞移植(hct)。

2025年2月15日 · Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin’s lymphoma that arises from the germinal center. It represents a heterogeneous disease characterized by different pathological, clinical, and molecular entities.

Diffuse large B-cell lymphoma (DLBCL) comprises a heterogeneous group with pathophysiological, genetic and clinical features. Many patients can be cured with R-CHOP therapy, which is the current standard regimen. Despite recent progress in improving patient survival, the 40% survival of DLBCL patients remains poor.

2025年1月20日 · Haematopoietic stem cell transplantation (HSCT) and CD19-targeted chimeric antigen receptor (CAR) T cells are potentially curative therapies for relapsed and/or refractory diffuse large B cell...

2021年3月3日 · ABC denotes activated B-cell–like, CNS central nervous system, DA-EPOCH-R dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with rituximab, DLBCL diffuse large...